{"resourceType": "EvidenceVariable", "meta": {"versionId": "64", "lastUpdated": "2024-11-22T11:55:46.474Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"]}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/236950", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}], "title": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "relatedArtifact": [{"type": "part-of", "resourceReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}, {"type": "cite-as", "citation": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing\u00ae: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236950. Revised 2024-10-03. Available at: https://fevir.net/resources/EvidenceVariable/236950. Computable resource at: https://fevir.net/resources/EvidenceVariable/236950."}], "definition": {"concept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "defined-in-handling-and-category", "display": "Defined in handling and category elements"}]}}, "handling": "dichotomous", "category": [{"name": "SGLT2 inhibitors", "valueReference": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors", "reference": "Group/236769"}}, {"name": "GLP-1 RA", "valueReference": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-comparator-85394-C-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Glucagon-Like Peptide-1 (GLP-1) receptor agonists", "reference": "Group/236776"}}], "url": "https://fevir.net/resources/EvidenceVariable/236950", "id": "236950", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "description": "This example of a GroupAssignment Profile describes a 2-group study (so handling='dichotomous') and lists the 2 study arms in category.name elements. Because the definition of this EvidenceVariable Resource is fully expressed in the handling and category elements, the definition.concept element uses a CodeableConcept for 'Defined in handling and category elements'.", "name": "GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA"}